Mode
Text Size
Log in / Sign up

Chronic kidney disease prevalence of 13.7% identified across 19 African countriesNew data shows high rates of kidney disease across Africa

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that CKD prevalence in Africa is 13.7% (stages 1-5), highlighting a significant public health burden.

This systematic review and meta-analysis evaluated the prevalence of chronic kidney disease (CKD) among adults residing in Africa. The study analyzed data from 91,723 participants across community-based settings in 19 different countries. The primary objective was to determine the pooled prevalence of CKD and identify geographic variations within the continent.

The analysis focused on identifying the presence of CKD as the primary exposure. While specific interventions or comparative treatments were not the focus of this review, the study provided a comprehensive overview of the disease burden across diverse populations in Africa. The data included participants from various regions to provide a broad epidemiological snapshot.

The primary outcome was the pooled prevalence of CKD stages 1 through 5. The analysis reported a pooled prevalence of 13.7% (95% CI, 11.0-16.4) among the 91,723 participants. For more advanced stages, specifically CKD stages 3 to 5, the study reported a pooled prevalence of 5.1% (95% CI, 4.3-5.8). These figures provide a baseline for understanding the scale of renal impairment in these regions.

A key secondary outcome was the assessment of regional variation in CKD prevalence. The analysis found significant heterogeneity with an I value greater than 98% and a p-value less than 0.001. Specifically, the data indicated a higher prevalence of CKD in Western Africa compared to Southern Africa. This suggests that geographic location may influence the prevalence of renal disease, potentially due to varying environmental factors or access to care.

Safety and tolerability data were not reported for this study as it was an observational meta-analysis of prevalence rather than a clinical trial of a specific intervention. Consequently, no adverse events, serious adverse events, or discontinuation rates were available for review.

These findings contribute to the understanding of CKD burden in Africa, though they do not directly compare against specific pharmacological interventions like Finerenone or GLP-1 receptor agonists mentioned in other literature. The study provides a foundational epidemiological context that underscores the need for systemic management of renal health in these populations.

Several methodological limitations were noted. These include variations in the quality of the included study data and substantial heterogeneity in prevalence estimates. Furthermore, there was a lack of specific assessment of chronic CKD as opposed to general CKD. The analysis also relied on aggregated data for 55% of the sample, and gaps in geographic representation may limit the ability to generalize these findings to all regions within Africa. The clinical implications are significant for public health planning. The high prevalence rates highlight a substantial burden and underscore the potential value of early detection programs. However, because the study did not specifically assess 'chronic' CKD and had some data limitations, clinicians should interpret these figures as a broad epidemiological indicator rather than a precise tool for individual patient risk stratification. Several questions remain unanswered regarding the specific drivers of the higher prevalence in Western Africa compared to Southern Africa. Additionally, more granular data on the transition from early-stage CKD to advanced stages (3-5) across different demographics would provide further clarity on the progression of the disease in these populations.

How this fits prior evidence

How this fits prior evidence: This meta-analysis provides a large-scale epidemiological baseline for CKD prevalence in Africa, which informs the scope of the public health burden. While it does not directly address the mechanisms of inflammation and immune dysregulation or the specific efficacy of treatments like Finerenone or GLP-1 receptor agonists, it quantifies the population size affected by the conditions these interventions aim to manage.

Living with a chronic illness can change everything for a person. For those with kidney disease, the challenge is often finding out about the problem early enough to manage it effectively. This latest research looks at how common this condition is across different regions in Africa, providing a clearer picture of the health challenges facing millions of people in these communities.

The researchers conducted a large-scale review of data from over 91,000 adults living in community settings across 19 different African countries. By looking at such a massive group of people, they were able to get a much clearer sense of how many people are affected by kidney issues compared to smaller, local studies. This type of broad look helps health officials see where the biggest needs are located.

The results showed that about 13.7% of the adults studied had some form of chronic kidney disease (CKD). When looking specifically at more advanced stages of the disease, the numbers were lower but still significant, with about 5.1% of people showing signs of more severe issues. The study also found a major difference in where these cases were most common. For example, the rates were much higher in Western Africa compared to Southern Africa.

While these findings are important for planning healthcare, there are some reasons to be cautious about how we interpret them. The researchers noted that the quality of the data varied between different studies. They also pointed out that they could not specifically measure if the kidney disease was long-term or chronic in every single case. Because much of the information came from combined reports rather than individual checkups, there is some uncertainty in the exact numbers.

For patients and families right now, this study does not offer a new treatment or a specific medical change. Instead, it highlights a major public health concern. It shows that kidney disease is very common in these regions, which means that finding ways to catch the problem early is vital. For anyone living with these symptoms, the most important step remains working closely with a healthcare provider to monitor kidney function and manage health proactively.

What this means for you:
Over 13% of adults in the study had kidney disease, highlighting a major need for early detection in Africa.

Study Details

Study typeMeta analysis
Sample sizen = 91,723
EvidenceLevel 1
PublishedJul 2026
View Original Abstract ↓
RATIONALE & OBJECTIVE: Chronic kidney disease (CKD) is a global public health concern, but its burden in Africa is poorly defined. This study estimated CKD prevalence across the African continent. STUDY DESIGN: Systematic review and individual participant data meta-analysis. SETTING & STUDY POPULATION: Populations residing in Africa. SELECTION CRITERIA: Eligible studies enrolled ≥300 adults, were observational, used community-based designs, and reported CKD prevalence or data necessary to calculate it. SEARCH STRATEGY: Studies, both published and unpublished, through May 31, 2024, identified through systematic searches of major databases and through networks within the CKD-Africa Collaboration. DATA EXTRACTION: Data were systematically extracted and verified by the authors. Extracted information included study and publication details, CKD diagnostic criteria, and participant characteristics. ANALYTICAL APPROACH: Pooled prevalence estimates were calculated using random-effects meta-analysis. RESULTS: Sixty-seven studies, comprising 91,723 participants from 19 countries, were included. High- and moderate-quality studies accounted for 37% and 52%, respectively, and 6% were unpublished. Pooled CKD prevalence (stages 1-5) was 13.7% (95% CI, 11.0-16.4), and 5.1% (95% CI, 4.3-5.8) for stages 3-5. Regional variation was evident (I >98%; P < 0.001), with higher prevalence in western Africa compared to southern Africa. Estimates using aggregated data and individual participant data were consistent. LIMITATIONS: Variations in the quality of the study data and substantial heterogeneity in prevalence estimates. Lack of assessment of chronic CKD. Reliance on aggregated data for 55% of the sample. Gaps in geographic representation may limit the generalizability of findings. CONCLUSIONS: Approximately 14% of African adults had CKD, highlighting its public health burden. The precision of this finding was augmented by the use of individual participant data. REGISTRATION: Registered at Prospero with identification number CRD42019143370. PLAIN-LANGUAGE SUMMARY: Chronic kidney disease (CKD), a long-term condition in which the kidneys gradually lose their ability to filter waste and fluids from the blood, is an increasing health problem in Africa, but prevalence data have been limited. Previous studies relied on only summaries of studies' data. This analysis combined individual-level and summary data from multiple African countries to provide a more accurate and precise estimate of CKD prevalence. It found that CKD affects a substantial proportion of adults, with rates varying across regions. These findings highlight the potential value of early detection given the availability of effective clinical strategies to manage CKD.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.